array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2432)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(55) "Regeneron patent victory 'a significant positive' - UBS"
["snippet_en"]=>
string(55) "Regeneron patent victory 'a significant positive' - UBS"
["url"]=>
string(115) "https://www.investing.com/news/stock-market-news/regeneron-patent-victory-a-significant-positive--ubs-432SI-3264471"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-12-28"
["categories"]=>
array(2) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(27) "Business Model & Innovation"
}
}
[1]=>
array(7) {
["title_en"]=>
string(57) "Regeneron surges after patent case ruling against Viatris"
["snippet_en"]=>
string(57) "Regeneron surges after patent case ruling against Viatris"
["url"]=>
string(120) "https://www.investing.com/news/stock-market-news/regeneron-surges-after-patent-case-ruling-against-viatris-432SI-3264127"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-12-27"
["categories"]=>
array(5) {
[0]=>
string(21) "Intellectual Property"
[1]=>
string(16) "Case Settlements"
[2]=>
string(8) "Verdicts"
[3]=>
string(5) "Legal"
[4]=>
string(27) "Business Model & Innovation"
}
}
[2]=>
array(7) {
["title_en"]=>
string(74) "Regeneron Gains After Eye-Drug Patent Victory Over Viatris - BNN Bloomberg"
["snippet_en"]=>
string(197) "Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc."
["url"]=>
string(96) "https://www.bnnbloomberg.ca/regeneron-gains-after-eye-drug-patent-victory-over-viatris-1.2015908"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/934626b6-ebe5-4ae4-9ef1-c56964bc6283"
["source"]=>
string(15) "bnnbloomberg.ca"
["publication_date"]=>
string(10) "2023-12-27"
["categories"]=>
array(4) {
[0]=>
string(8) "Verdicts"
[1]=>
string(21) "Intellectual Property"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
}
}
[3]=>
array(7) {
["title_en"]=>
string(64) "Regeneron Concession Narrows Covid Antibody-Cocktail Patent Suit"
["snippet_en"]=>
string(297) "Regeneron Pharmaceuticals Inc. agreed that its Covid-19 “antibody cocktail” was developed using technology that, unless it’s found to be shielded from liability under a legal “safe harbor,” would infringe a California biotechnology company’s valid patent, in a deal narrowing the case."
["url"]=>
string(101) "https://news.bloomberglaw.com/ip-law/regeneron-concession-narrows-covid-antibody-cocktail-patent-suit"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/1f16816e-6a27-4622-9297-4857e7873aee"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-09-19"
["categories"]=>
array(5) {
[0]=>
string(5) "R & D"
[1]=>
string(5) "Legal"
[2]=>
string(8) "Epidemic"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(26) "Product Quality and safety"
}
}
[4]=>
array(7) {
["title_en"]=>
string(69) "The patent is granted for a process control method for chromatography"
["snippet_en"]=>
string(299) "Regeneron Pharmaceuticals Inc's patent outlines a comprehensive process control method for chromatography data analysis. By applying noise reduction techniques, performing transition analysis, and taking appropriate actions, this method aims to improve the accuracy and reliability of chromatography"
["url"]=>
string(167) "https://www.pharmaceutical-technology.com/data-insights/regeneron-pharmaceuticals-gets-grant-for-the-patent-is-granted-for-a-process-control-method-for-chromatography/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-08-18"
["categories"]=>
array(1) {
[0]=>
string(27) "Business Model & Innovation"
}
}
[5]=>
array(7) {
["title_en"]=>
string(23) "Aflibercept IPR Updates"
["snippet_en"]=>
string(198) "On July 19 and 20, 2023, the PTAB granted institution of IPR2023-00442, filed by Samsung Bioepis regarding Regeneron's Patent No. 10,130,681 which is directed to treating angiogenic eye disorders..."
["url"]=>
string(74) "https://www.mondaq.com/unitedstates/patent/1349388/aflibercept-ipr-updates"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/142ae27a-70c0-4f02-a708-f41ddf09c728"
["source"]=>
string(10) "mondaq.com"
["publication_date"]=>
string(10) "2023-08-01"
["categories"]=>
array(1) {
[0]=>
string(27) "Business Model & Innovation"
}
}
[6]=>
array(7) {
["title_en"]=>
string(61) "Regeneron Escapes Viatris Counterclaims Ahead of Patent Trial"
["snippet_en"]=>
string(277) "Regeneron Pharmaceuticals Inc. won a judgment clearing it of Viatris Inc.’s inequitable-conduct counterclaims regarding two of three patents that Regeneron alleges a proposed biosimilar of Eylea infringes ahead of next week’s bench trial over the retinal-disease treatment."
["url"]=>
string(98) "https://news.bloomberglaw.com/ip-law/regeneron-escapes-viatris-counterclaims-ahead-of-patent-trial"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9c7a2e7d-b731-471c-ad07-d3ae47bbab6a"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-06-07"
["categories"]=>
array(4) {
[0]=>
string(5) "Award"
[1]=>
string(21) "Intellectual Property"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
}
}
[7]=>
array(7) {
["title_en"]=>
string(99) "Breaking: SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen"
["snippet_en"]=>
string(295) "In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The win for Sanofi and Regeneron is a setback for"
["url"]=>
string(118) "https://endpts.com/breaking-scotus-rules-unanimously-in-favor-of-sanofi-and-regeneron-in-pcsk9-patent-spat-with-amgen/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ce204c3a-e60c-49a3-8b35-d97303cbe08b"
["source"]=>
string(10) "endpts.com"
["publication_date"]=>
string(10) "2023-05-18"
["categories"]=>
array(4) {
[0]=>
string(11) "US Politics"
[1]=>
string(5) "Legal"
[2]=>
string(8) "Verdicts"
[3]=>
string(27) "Business Model & Innovation"
}
}
[8]=>
array(7) {
["title_en"]=>
string(50) "Don’t distort enablement law, Amgen tells SCOTUS"
["snippet_en"]=>
string(151) "Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand."
["url"]=>
string(94) "https://www.lifesciencesipreview.com/news/don-t-distort-enablement-law-amgen-tells-scotus-5048"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0383aaa7-a77b-4dd3-ae26-0eeb314bf23b"
["source"]=>
string(24) "lifesciencesipreview.com"
["publication_date"]=>
string(10) "2023-03-09"
["categories"]=>
array(5) {
[0]=>
string(8) "Verdicts"
[1]=>
string(46) "Management of Legal and Regulatory Environment"
[2]=>
string(5) "Legal"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(15) "Business Ethics"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(99)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[22]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2432 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc.
Regeneron Pharmaceuticals Inc. agreed that its Covid-19 “antibody cocktail” was developed using technology that, unless it’s found to be shielded from liability under a legal “safe harbor,” would infringe a California biotechnology company’s valid patent, in a deal narrowing the case.
Regeneron Pharmaceuticals Inc's patent outlines a comprehensive process control method for chromatography data analysis. By applying noise reduction techniques, performing transition analysis, and taking appropriate actions, this method aims to improve the accuracy and reliability of chromatography
On July 19 and 20, 2023, the PTAB granted institution of IPR2023-00442, filed by Samsung Bioepis regarding Regeneron's Patent No. 10,130,681 which is directed to treating angiogenic eye disorders...
Regeneron Pharmaceuticals Inc. won a judgment clearing it of Viatris Inc.’s inequitable-conduct counterclaims regarding two of three patents that Regeneron alleges a proposed biosimilar of Eylea infringes ahead of next week’s bench trial over the retinal-disease treatment.
In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The win for Sanofi and Regeneron is a setback for
Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
